50 years of Sensodyne® innovation 1961-2011
Leading the way with Sensodyne

For the last 50 years Sensodyne has been at the forefront of scientific innovation into the aetiology, treatment and prevention of dentine hypersensitivity and erosive tooth wear. In January 2011 GlaxoSmithKline celebrated 50 Years of Sensodyne innovation by hosting a 50th anniversary symposium in Madrid, Spain. Experts in the field of dentistry and dental research discussed the past, present and most importantly the future of oral health, each presenting a prospective from their own field of specialism.

Principal Speakers
The principal speakers at the symposia included Professor Francis Hughes, Professor J.M. ('bob') ten Cate, Professor David Bartlett and Professor Martin Addy.

All Speakers agreed that dentistry had come a long way in 50 years however good oral health for all is a challenge and can only be achieved by linking treatment to patient needs. “Research into genetic profiling holds many possibilities.” Professor Francis Hughes.

Oral Health prevention, a relatively neglected area of global health, is now key and commitment is needed by policy makers to prevent chronic diseases. “The effectiveness and contribution of fluoride toothpastes are undisputed, however in the future priorities should include ‘Better’ or ‘Smarter’ products that improve compliance, availability and affordability. Every one can learn to brush - however a paradigm shift in prevention needs to occur, as caries prevention is very dependent on fluoride.” Professor J.M. ('bob') ten Cate.

“In future there will be reduced government funding for dentistry practice and research, therefore there is a need for Industry and University collaboration with research focused on clinical needs and realistic outcomes. Prevention of erosion needs changes to formulation of toothpastes which actively protect enamel and dentine from acids”. Professor David Bartlett.

“Traditionally there has been a lack of understanding of the aetiology of hypersensitivity and gingival recession. For dentists to offer advice they need to be educated and Industry has a role”. Professor Martin Addy. Professor Addy called for further research that is fully scientifically founded. “Many clinical trials on treatments for Dentine Hypersensitivity belong in the realms of testimonials. Areas for improvement include Objective Evaluation Criteria, better controls and evidence of stimulus response and therapeutic action. There is a need to be able to really magnify and visualise Dentine either as a replica or in-situ”.

“Industry has a key role to play in the continuing research and development of preventative dental care.”

Science at the heart of the care of Sensodyne success for 50 years. Through collaboration with the dental health care professional and by researching patient’s needs, truly significant advances have been made. Sensodyne was first made available in 1961 by Block Drug. Since GlaxoSmithKline’s acquisition of the brand it has rapidly grown globally and become the dentists sensitivity toothpaste of choice in many markets.

Expanding expertise
GlaxoSmithKline’s significant investment in Sensodyne includes employing experts not only in dentistry but also in fields outside to expand the understanding of dentine hypersensitivity. Linking aetiology, research and patient needs has resulted in toothpastes that deliver specific patient benefits.
Welcome to a new layer of expertise in dentine hypersensitivity

Today you can go further than treating the pain of dentine hypersensitivity.

Today you have new Sensodyne® Repair & Protect containing NovaMin® calcium phosphate technology.

NovaMin® builds a reparative hydroxyapatite-like layer over exposed dentine and within the tubules.

Starting to form from the first use, this reparative layer creates an effective and lasting barrier to the pain of dentine hypersensitivity.

Visual representation of dentine cross-section and dynamic reparative layer